research peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-09 and is reviewed periodically as new material appears.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
== External links == Daintith, John (18 August 2008). Biographical Encyclopedia of Scientists (Third ed.). CRC Press. ISBN 978-1-4200-7272-3 – via Google Books. "Sidney W. Fox; Analyzed First Moon Rocks". 18 August 1998 – via LA Times. Fox, Sidney W.; Harada, Kaoru (1958). "Thermal Copolymerization of Amino Acids to a Product Resembling Protein". Science. 128 (3333): 1214. Bibcode:1958Sci...128.1214F. doi:10.1126/science.128.3333.1214. JSTOR 1756313. PMID 13592311. Fox, Sidney W. (1957). "The chemical problem of spontaneous generation". Journal of Chemical Education. 34 (10): 472. Bibcode:1957JChEd..34..472F. doi:10.1021/ed034p472.
In June 2015, the United States Office of Personnel Management (OPM) announced that it had been the target of a data breach targeting the records of as many as four million people. Later, FBI Director James Comey put the number at 18 million. The Washington Post has reported that the attack originated in China, citing unnamed government officials. Operation Shady RAT is a series of cyber attacks starting mid-2006, reported by Internet security company McAfee in August 2011. China is widely believed to be the state actor behind these attacks which hit at least 72 organizations including governments and defense contractors. The 2018 cyberattack on the Marriott hotel chain that collected personal details of roughly 500 million guests is now known to be a part of a Chinese intelligence-gathering effort that also hacked health insurers and the security clearance files of millions more Americans, The hackers, are suspected of working on behalf of the Ministry of State Security (MSS), the country's Communist-controlled civilian spy agency. On 14 September 2020, a database showing personal details of about 2.4 million people around the world was leaked and published. A Chinese company, Zhenhua Data compiled the database. According to the information from "National Enterprise Credit Information Publicity System", which is run by State Administration for Market Regulation in China, the shareholders of Zhenhua Data Information Technology Co., Ltd. are two natural persons and one general partnership enterprise whose partners are natural persons.
=== Se–So === Michael Sela (1924–2022). Israeli immunologist at the Weizmann Institute, who worked on synthetic antigens, molecules that trigger the immune system to attack. Foreign associate Natl. Acad. Sci. USA. Nathan Sharon (1925–2011). Israeli biochemist at the Weizmann Institute of Science, expert on carbohydrates and glycoproteins. Member of the Israel Academy of Sciences and Humanities. Anatoly Sharpenak (1895–1969). Russian biochemist at the Russian Academy of Medical Sciences, who studied protein metabolism, and the aetiology and pathogenesis of dental caries. Sofia Simmonds (1917–2007). American biochemist at Yale known for work on amino acid and peptide metabolism. Karl Slotta (1895–1987). German-American biochemist at the University of Miami who discovered progesterone and studied snake venoms. Emil L. Smith (1911–2009). American protein chemist at UCLA, known in particular for studies of protein evolution. Member Natl. Acad. Sci. USA. Michael Smith (1932–2000), Canadian biochemist at the University of Wisconsin–Madison. Nobel Prize in Chemistry for developing site-directed mutagenesis Oliver Smithies FRS (foreign associate) (1925–2017). British-American geneticist and physical biochemist at the University of North Carolina at Chapel Hill who introduced starch as a medium for gel electrophoresis. Nobel Prize in Physiology or Medicine in 2007. Liz Specht (21st century). American research scientist specializing in chemical engineering and synthetic biology Alberto Sols (1917–1989). Spanish biochemist at the Spanish National Research Council.
The energy released by the Hiroshima bomb explosion (about 15 kt TNT equivalent, or 6×1013 J) is often used by geologists as a unit when describing the energy of earthquakes, volcanic eruptions, and asteroid impacts. Prior to the detonation of the Hiroshima bomb, the size of the Halifax Explosion (about 3 kt TNT equivalent, or 1.26×1013 J), was the standard for this type of relative measurement. Each explosion had been the largest known artificial detonation to date.
The EU adopted the listing of PFOA in Annex A of the Stockholm Convention with Commission Delegated Regulation (EU) 2020/784 of 8 April 2020 and introduced a limit value of 0,025 mg/kg for PFOA including its salts, and at 1 mg/kg for the individual PFOA-related compounds or a combination of those compounds. They also included some specific exemptions. Among them is a time-bound exemption for PFOA in fire-fighting foam.
Sources: en.wikipedia.org
=== Overview === Before taking office, Maryland's economic outlook was among the lowest in the nation, according to the American Legislative Exchange Council. Over the past decade, the state's gross domestic product (GDP) had only grown by 11 percent, compared to a 23 percent growth nationally, and ranked in the bottom 10 states in several economic factors, including economic momentum, change in personal income, and population growth. At the same time, the state had a $2.5 billion budget surplus from a combination of federal pandemic aid and a tightening of state spending, $2.9 billion in its "rainy day fund", and low unemployment numbers. By May 2026, Maryland's unemployment rate had nearly doubled as a result of federal mass layoffs as well as cuts to federal contracts and grants—which Maryland's economy is heavily reliant on—by the second Trump administration. During the 2023 legislative session, Moore introduced the Innovation Economy Infrastructure Act, which would provide $10 million in grants for "infrastructure projects in eligible technology sectors"; the Access to Banking Act, which incentives banking institutions to locate in low- and moderate-income areas of the state; and the Broadband Expansion Act, which initially offered tax incentives to the broadband internet industry but was later watered down to a bill to study how to incentivize broadband expansion. All three bills were signed into law in May 2023.
== Embryonic development == During embryo development in mice, CCN1 is highly expressed in the cardiovascular, skeletal, and neuronal systems. CCN1 knockout mice are embryonic lethal due to defects in cardiac septal morphogenesis, deficient blood vessel formation in placenta, and compromised vascular integrity. In Xenopus laevis, CCN1 is required for normal gastrulation and modulation of Wnt signaling.
Cube sugar (sometimes called sugar lumps) are white or brown granulated sugars lightly steamed and pressed together in block shape. They are used to sweeten drinks. Sugarloaf was the usual cone-form in which refined sugar was produced and sold until the late 19th century.
9 September – Police in the Pakistani city of Jhelum say they have detained ten relatives of Urfan Sharif, the father of Sara Sharif, for questioning. 10 September – Nine vehicles are damaged when a privately owned military truck is driven through a police roadblock at Norton Fitzwarren, near Taunton, Somerset. A man is subsequently charged over the incident. 11 September – England's Autumn 2023 flu vaccination and COVID-19 booster programme begins, having been brought forward from October due to the BA.2.86 variant. The grandfather of Sara Sharif tells BBC News that five children who travelled to Pakistan with the dead girl's father have been taken by police. A judge subsequently rules that the children should be sent to a government childcare facility. Transport for London bans an advert for an artisan cheese after the product is deemed to be too unhealthy. 12 September – An inquest into the death of Melissa Kerr, a 31-year-old woman from Gorleston, Norfolk, who died after undergoing buttocks enlargement surgery at a private clinic in Turkey in 2019, concludes she was not given enough information concerning the risks. 13 September – Three adults who police want to speak to about the death of Sara Sharif return to the UK from Pakistan, and are arrested on suspicion of murder. The Independent Office for Police Conduct is to investigate Greater Manchester Police over its handling of the wrongful conviction of Andrew Malkinson.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.